Abstract
Severe acute respiratory syndrome corona virus 2(SARS-CoV-2), the cause of coronavirus disease- 2019 (COVID-19) after emerging in china in late 2019 is spreading rapidly across the world. The most common cause of death in patient with COVID-19 is the rapid progression of acute respiratory distress syndrome (ARDS) shortly after the beginning of dyspnea and hypoxemia. Patients with severe COVID-19 may also develop acute cardiac, kidney and liver injury that are associated with poor prognosis and can lead to high mortality rate. Numerous randomized trials are ongoing to find an effective, safe and widely available treatment. Remdisivir is the only FDA -approved antiviral agent for treatment of severe COVID-19. Glucocorticoids (GCs) have been used for treatment of cytokine storm syndrome and respiratory failure in hospitalized patient with severe covid-19. One of the therapeutic effects of GCs is stability of vascular endothelial barrier and decreasing tissue edema. In our opinion, the decreasing vascular permeability effect of glucocorticoids in the injured myocardium might has an important additional factor in reducing mortality in severe, hospitalized COVID-19 patients.
【초록키워드】 COVID-19, Treatment, coronavirus disease, Glucocorticoids, Corona virus, ARDS, coronavirus, Hospitalized, Respiratory failure, severe COVID-19, acute respiratory distress syndrome, Antiviral, randomized trial, cytokine, vascular permeability, Cytokine storm syndrome, progression, FDA, virus, glucocorticoid, kidney, Severe acute respiratory syndrome, stability, Hypoxemia, Dyspnea, Patient, edema, death, Liver injury, respiratory, antiviral agent, cause of death, acute respiratory distress, Safe, lead, respiratory distress, endothelial, acute respiratory syndrome, Myocardium, Vascular, hospitalized COVID-19 patients, tissue, Severe Acute Respiratory Syndrome Corona Virus, syndrome, poor prognosis, therapeutic effects, reducing mortality, therapeutic effect, high mortality rate, patient with COVID-19, effective, gcs, develop, Numerous, 【제목키워드】 COVID-19, Dexamethasone, Myocardial,